1

Editorial: MOVEMENT DISORDERS IN THE WORLD OF COVID-19

Year:
2020
Language:
english
File:
PDF, 1.28 MB
english, 2020
10

Immunotherapy for Parkinson's disease: stay tuned

Year:
2020
File:
PDF, 86 KB
2020
12

Movement Disorders : New Faces, Same Journal

Year:
2020
Language:
english
File:
PDF, 178 KB
english, 2020
13

Dyskinesias and levodopa therapy: why wait?

Year:
2018
Language:
english
File:
PDF, 1.88 MB
english, 2018
14

The placebo effect in Parkinson's disease

Year:
2002
Language:
english
File:
PDF, 338 KB
english, 2002
18

DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS

Year:
1986
Language:
english
File:
PDF, 397 KB
english, 1986
20

DAT-SPECT diagnoses dopamine depletion, but not PD

Year:
2014
Language:
english
File:
PDF, 112 KB
english, 2014
22

Challenges and unfulfilled promises in Parkinson's disease

Year:
2017
Language:
english
File:
PDF, 44 KB
english, 2017
24

Gene therapy for Parkinson's disease: early data

Year:
2007
Language:
english
File:
PDF, 154 KB
english, 2007
29

The biochemical bases of the placebo effect

Year:
2004
Language:
english
File:
PDF, 173 KB
english, 2004
32

Assessing the integrity of the dopamine system in Parkinson's disease: How best to do it?

Year:
2001
Language:
english
File:
PDF, 20 KB
english, 2001
34

Neuroimaging in the early diagnosis of neurodegenerative disease

Year:
2012
Language:
english
File:
PDF, 179 KB
english, 2012
35

Positron emission tomography in premotor Parkinson's disease

Year:
2007
Language:
english
File:
PDF, 75 KB
english, 2007
41

Central pharmacokinetics of levodopa: Lessons from imaging studies

Year:
2015
Language:
english
File:
PDF, 494 KB
english, 2015
44

Effects of ageing on tachykinin function in the basal ganglia

Year:
1993
Language:
english
File:
PDF, 690 KB
english, 1993
50

Treatment for the progression of Parkinson's disease

Year:
2005
Language:
english
File:
PDF, 260 KB
english, 2005